arrow
返回

Predicting resistance mutations using protein design algorithms

delete2010-07-19
delete124
delete
OA
AI
K
Kathleen M. Frey
I
Ivelin S. Georgiev
B
Bruce R. Donald *
A
Amy C. Anderson
DOI:10.1073/pnas.1002162107delete
delete原文链接
delete分享
delete收藏
查看原文
摘要

摘要

En 中文
Drug resistance resulting from mutations to the target is an unfortunate common phenomenon that limits the lifetime of many of the most successful drugs. In contrast to the investigation of mutations after clinical exposure, it would be powerful to be able to incorporate strategies early in the development process to predict and overcome the effects of possible resistance mutations. Here we present a unique prospective application of an ensemble-based protein design algorithm, K*, to predict potential resistance mutations in dihydrofolate reductase from Staphylococcus aureus using positive design to maintain catalytic function and negative design to interfere with binding of a lead inhibitor. Enzyme inhibition assays show that three of the four highly-ranked predicted mutants are active yet display lower affinity (18-, 9-, and 13-fold) for the inhibitor. A crystal structure of the top-ranked mutant enzyme validates the predicted conformations of the mutated residues and the structural basis of the loss of potency. The use of protein design algorithms to predict resistance mutations could be incorporated in a lead design strategy against any target that is susceptible to mutational resistance.
Keyword:
negative design algorithm
DHFR
MRSA
K* design algorithm
AI总结

AI总结

对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

P
Proceedings of the National Academy of Sciences of the United States of America
IF:
9.1
论文数:
10.8W
被引数:
73.5W

机构

D
Duke University
学者数:
6.3W
论文数: 5.7W
被引数: 6.5W
U
University of Connecticut
学者数:
2.4W
论文数: 2.2W
被引数: 2.5W
引用论文

引用论文

Computational design of antibody-affinity improvement beyond in vivo maturation
err2007-09-23
err394
errOAAI
errLippow, Shaun M.; Wittrup, K. Dane; Tidor, Bruce
err分享
err收藏
err分享
err收藏
Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors
errGut
IF0
err2008-02-13
err0
PREAI
errR Moucari; P-E Rautou; D Cazals-Hatem; A Geara; C Bureau; Y Consigny; C Francoz; M-H Denninger; V Vilgrain; J Belghiti; F Durand; D Valla; A Plessier
err分享
err收藏
学者 查看更多内容